Transplante de células-tronco de doador não aparentado com sucesso após transplante de células de cordão umbilical não aparentado em paciente com leucemia linfocítica aguda. À procura do efeito enxerto versus leucemia

Successful stem cell transplantation from an unrelated donor after an unrelated cord blood transplantation in an acute lymphocytic leukemia patient: Searching for the graft versus leukemia effect

Nelson Hamerschlak¹
Fabio P. S. Santos²
José Mauro Kutner²
Andreza A. F. Ribeiro²
Marcos de Lima³

¹ Head of Hematology Department – Hospital Albert Einstein, São Paulo-SP – Brazil.
² Bone Marrow Transplantation Unit, Hospital Israelita Albert Einstein, São Paulo-SP – Brazil.
³ Department of Stem Cell Transplantation and Cell Therapy, M. D. Anderson Cancer Center, Houston, Texas, USA

No matched, related donors were available, but a 6/6 HLA matched CB unit was identified (intermediate for HLA-A and -B, and high-resolution for HLA-DRB1), with total nucleated cell count of 3.14x10⁷/kg. Conditioning consisted of cyclophosphamide 60mg/kg once daily (days -6 and -5) and fractionated total-body irradiation (1200cGy in six fractions, days -4, -3 and -2). Graft versus host disease (GVHD) prophylaxis was cyclosporine 5mg/kg in two doses daily (starting on day -2) and short-course methotrexate (15mg/m² on day +1, and 10mg/m² on days +3, +6 and +11). Neutrophils and platelets engraftment occurred on transplant days 14 and 24. Day +30 chimerism was 100% done by fluorescent in situ hybridization (FISH) analysis for the Y chromosome. There was no acute or chronic GVHD.

A second relapse was diagnosed 32 months post-transplant. Hyper-CVAD was used (no response) and subsequently, high-dose cytarabine and mitoxantrone, with a third CR. Complications included cryptococcal pneumonia. A 10/10 HLA matched unrelated donor was identified (intermediate for HLA-A, -B and C, and high-resolution for HLA-DRB1 and -DQB1). Busulfan 130mg/m² (on days -6, -5, -4 and -3) and fludarabine 40mg/m² (on days -6, -5, -4 and -3) were administered, both once daily.² GVHD prophylaxis was done with tacrolimus (dose adjusted to maintain whole blood through levels between 5 and 15ng/ml), and mini-dose methotrexate (5mg/m² on days +1, +3, +6 and +11). The peripheral blood stem cell graft contained a total dose of CD34+ cells of 2.35 x 10⁶/kg. Neutrophil and platelet engraftment occurred on days +20 and +62. The patient developed grade II acute and extensive chronic GVHD; multiple episodes of citomegalovirus reactivation, and pulmonary aspergillosis, but recovered fully. She is alive, in good performance status and in CR 30 months post-second transplant.

There is no established treatment for ALL relapsing after allo HSCT. The main options are to perform a second allo HSCT or the use of immunotherapy in the form of donor lymphocyte infusions, but results are usually poor, due to low efficacy of salvage chemotherapy that precedes transplant, high toxicities rates of the conditioning regimen, and the relative insensitivity of ALL to the graft-versus-leukemia (GVL) effect.³ Duration of remission after the first transplant, achievement of CR before the second procedure, age, and type of leukemia significantly influence the success of a second allo HSCT.³

Our patient received a CB transplant initially, and no cells were available for treatment of relapse (as expected). There are few reports of successful second allo SCT in this context.⁴ We only had time to search and secure an unrelated donor because the patient entered a third CR with Ara-C-based chemotherapy.³

There is no established conditioning regimen for a second allo HSCT in patients with ALL, especially after failure of TBI-based regimens. Reduced-intensity conditioning can be recommended, but reductions in dose intensity can be associated with increased likelihood of failure due to relapsed disease. We therefore chose to use ablative doses of
intravenous busulfan in combination with fludarabine, hypothesizing that it would provide enough myeloablation and immunosuppression while minimizing the risk of toxicity.

The patient developed chronic GVHD after the second transplantation, which likely contributed to the prolonged disease-free survival enjoyed so far. Even though it is largely believed that ALL is less responsive to the GVL effect, the development of chronic GVHD is associated with long term disease-free survival in advanced ALL, showing that GVL is important for the control of this disease.

Second ablative transplant from unrelated donor may be successfully offered to selected patients with ALL relapsing after CB transplants. The role of the GVHD/GVL phenomena was particularly important in this case.

Resumo


Palavras-chave: Transplante de células-tronco de sangue do cordão umbilical; transplante de células-tronco hematopoéticas; recidiva; leucemia linfóide.

References


Avaliação: Editor e dois revisores externos
Conflito de interesse: sem conflito de interesse

Recebido: 26/02/2009
Aceito: 12/03/2009

Hospital Albert Einstein

Correspondência: Nelson Hamerschlak
Bone Marrow Transplantation Unit, Hospital Israelita Albert Einstein
Av. Albert Einstein, 627 – Building Manoel T. Hidal – Room 1203
05652-000 – São Paulo-SP – Brazil
E-mail: hamer@einstein.br